US faces potential ‘transition’ to Kovid

Dr. Scott Gottlieb emphasized the importance of vaccinating more and more people, and warned of a potentially dire spring and summer without protective immunity as new Kovid variants appear around the world.

“If we can’t get more protective immunity in the population, then we can face a situation where we have, for example, a permanent infection growing in the spring and summer as these variants get a foothold here , “The former FDA chief said in an interview on CNBC’s” The News with Shepard Smith “Thursday evening.

Ohio State researchers found a new Kovid strain in the US with mutations that scientists haven’t seen before. He also revealed that he had received another strain that is similar to the high permeability of the United Kingdom. Researchers say these mutations are “likely to make the virus more contagious.”

Gottlieb warned that variants could change in a relatively cool spring and summer, “in summers where we have more infections because these variants are now spreading and they spread more easily, even in warmer months.” , When we really need shoulders. ” A lot of coronoviruses have spread in T. “

Longtime Harvard University professor Drs. David Edwards echoed Gottlieb’s sentiments on timing and the importance of an effective vacancy rollout.

“Time matters, of course, when encountering any organism,” FWEN founder Edwards called a nasal hygiene haze developed for the coronovirus epidemic. “Our primary goal this winter should still be to vaccinate as many people as we can with the very effective vaccines we have today.”

According to the Centers for Disease Control and Prevention, the US has distributed 30.6 million vaccines and distributed 11 million people. An estimate of the forecast compiled by the CDC, however, estimated that an additional 92,000 American Kovid would die in the next three weeks.

According to a CNBC analysis of Johns Hopkins data, the United States has reported 8,400 deaths in the last two days and nearly 40,000 deaths in less than two weeks of 2021. The epidemic kills more than 3,300 Americans a day.

Gottlieb told host Shepard Smith that he had been “encouraged” by Johnson & Johnson’s one-dose vaccine and “confidently” to help the Kovid vaccine rollout across the US to increase its potential in building the company. is ready.

“Preliminary data seemed encouraging,” Gottlieb said. “One of the things we noticed in the data was that the antibody response persisted even after about a month and a half.”

Disclosure: Scott Gottlieb is a CNBC contributor and a member of the boards of Pfizer, genetic testing start-up temps and biotech company Illumina. Has a manufacturing agreement with Pfizer Gilead For Remedisvir. Also serves as co-chairman of Gottlieb Norwegian Cruise Line Holdings‘And Royal Caribbean“Healthy Cell Panel.”


Leave a Reply

Your email address will not be published.